Background and objectives Previous studies suggested that intravenous methylprednisolone possibly accelerates remission of proteinuria in adult-onset minimal change disease; its impact on relapse of proteinuria is unknown.
Introduction
Along with membranous nephropathy and FSGS, minimal change disease (MCD) is one of the major glomerulonephritides in adult patients with primary nephrotic syndrome (1) (2) (3) (4) (5) (6) and especially common in Asian countries (4) (5) (6) . Although few patients with MCD progress to ESRD, a series of studies reported that approximately 30%-70%, most commonly 60%, of adult MCD patients experienced at least one relapse of proteinuria (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) and that 50%-60% of patients with a first relapse subsequently experienced a second relapse (7) (8) (9) (10) (11) (12) . Thus, clinical goals in MCD patients are early induction of remission of proteinuria and more importantly, prevention of relapse of proteinuria.
A few small randomized controlled studies showed that intravenous methylprednisolone (mPSL) accelerated remission in MCD patients. An Italian randomized controlled trial showed that pediatric (not adult) MCD patients treated with mPSL and prednisone achieved remission earlier than those patients with prednisone alone (19) . In another Japanese nonrandomized controlled trial of adult MCD patients, initial mPSL use followed by cyclosporine (not a Departments of *Geriatric Medicine and Nephrology, and corticosteroid) resulted in shorter time to remission compared with cyclosporine monotherapy and prednisolone (PSL) monotherapy (20) . Although these studies showed that mPSL accelerated remission, no obvious impact on relapse was observed. By contrast, an interesting Japanese retrospective cohort study recently reported that adult MCD patients treated with mPSL followed by PSL (mPSL+PSL) experienced significantly earlier remissions and earlier relapses (13) , suggesting that mPSL did not benefit the long-term prognosis of adult MCD patients.
The purpose of this study was to assess the effectiveness of mPSL+PSL for first remission and first relapse of proteinuria in the largest retrospective adult MCD cohort worldwide, the Study of Outcomes and Practice Patterns of Minimal Change Disease (STOP-MCD), including 125 adult MCD patients (21) .
Materials and Methods

Patients
A multicenter retrospective cohort study, the STOP-MCD, included 147 adult patients ages 15 years or older who developed a first episode of nephrotic syndrome and were diagnosed with primary MCD by kidney biopsy between 2000 and 2009 in five nephrology centers in Japan (21) . We excluded 22 patients (15.0%) because of spontaneous remission of proteinuria (n=6), loss to follow-up without immunosuppressive therapy (n=3), initial use of nonsteroidal immunosuppressives (n=9), and missing data (n=4). Finally, this study included 125 MCD patients (85.0%) who initiated a corticosteroid as the first immunosuppressive therapy. According to the intention-to-treat principle, 125 patients were categorized into two groups: one group comprised 65 patients treated initially with intravenous mPSL followed by PSL (mPSL+PSL group), and the other group comprised 60 patients receiving initial therapy with PSL only (PSL group). The study protocol was approved by the ethical committees in each facility.
Measurements
Baseline characteristics preceding corticosteroid initiation were collected retrospectively from patients' medical records and included age, sex, body mass index, systolic and diastolic BPs, serum concentration of creatinine, total cholesterol, albumin, urinary protein (UP), intravenous administration of 25% human albumin, and initial doses of mPSL (0.5 or 1.0 g/d for 3 consecutive days) and PSL. Data on the use of mPSL, PSL, and other immunosuppressants during the follow-up period were also collected.
The outcomes of interest in this study were time from corticosteroid initiation to first remission of proteinuria and time from corticosteroid initiation to subsequent first relapses of proteinuria. Remission was defined as UP,0.3 g/d, UP/creatinine ratio,0.3, and/or negative to trace dipstick UP values. Relapse was defined as UP$1.0 g/d, UP/creatinine ratio$1.0, and/or dipstick UP value $1+ followed by an increase in corticosteroid dosing and/or add-on use of immunosuppressive agents after developing remission. Patients were followed up until December 2010 and censored at death (n=1) or on the last day of urinary examination before December 2010. For the duration of the observational period, we also collected information on hospitalization because of infection, surgical therapy for aseptic osteonecrosis or cataract, initiation of antidiabetic drugs, and diagnosis of gastroduodenal bleeding.
Because of the retrospective nature of this study, the immunosuppressive therapy protocol was not predetermined and depended exclusively on individual nephrologists. Details of use of immunosuppressants were obtained from patient medical records for the assessment of potential confounding by corticosteroid dose and concurrent use of other immunosuppressants during the follow-up period. The cumulative PSL dose was calculated by conversion of the mPSL dose (1 mg mPSL was considered equivalent to 1.25 mg PSL) (22, 23) .
Statistical Analyses
Between-group comparisons of clinical characteristics were performed using the unpaired t test or Wilcoxon's rank-sum test for continuous variables and the chi-squared test or Fisher's exact test for categorical variables as appropriate. Because of the highly skewed distributions of serum creatinine and UP, their natural logarithms were used in subsequent analyses.
Cumulative probabilities of first remission and first relapse were calculated using Kaplan-Meier methods. The effectiveness of mPSL+PSL and PSL on these outcomes was compared using the log-rank test and univariate and multivariate Cox proportional hazards (CPH) models. The proportional hazards assumption for covariates was tested by using scaled Schoenfeld residuals. We performed a propensity score (PS) analysis to estimate the probability of initial mPSL+PSL therapy to control for the imbalance of the baseline characteristics between the mPSL+PSL and PSL groups (24) . The PS was calculated using a multivariate logistic regression model including baseline age, sex, body mass index, systolic BP, antihypertensive use, serum albumin and creatinine concentration with logarithmic transformation, urinary protein with logarithmic transformation, and use of intravenous 25% albumin as independent variables. Calibration was assessed using the Hosmer-Lemeshow goodness-of-fit test. The area under the receiver operating characteristics curve was calculated to assess the predictive ability of the PS. After PS calculations, associations between the initial use of mPSL+PSL and the study outcomes were examined in CPH models stratified by PS tertiles and matched by PS. In the PS-matching analysis, each patient in the mPSL+PSL group was matched to a patient in the PSL group with the nearest PS at a ratio of 1:1 without replacement using a greedy matching algorithm with a caliper width equal to 0.2 of the SD of the logit of the PS (25) . Differences in clinical characteristics between the matched pairs were assessed using paired t test or Wilcoxon's signed-rank test for continuous variables and McNemar's test for categorical variables as appropriate.
To assess the potential influence of corticosteroid dose and concurrent use of other immunosuppressants during follow-up between immunosuppressive therapy initiation and the first relapse (or censoring in patients without relapse), point use of immunosuppressants and point and cumulative PSL doses at 0, 1, 3, 6, 12, 18, and 24 months of immunosuppressive therapy were compared between the mPSL+PSL group and the PSL group. The point PSL dose was divided by body weight on the day of first remission or hospital discharge, whichever came first. To assess the effectiveness of initial mPSL use, we subtracted the initial mPSL dose (1 g [n=51] or 0.5 g [n=14] mPSL for 3 days, which is equivalent to 1.25 or 0.625 g PSL for 3 days, respectively) from the cumulative PSL dose in the mPSL+PSL group.
Continuous variables were expressed as mean6SD or median (interquartile range), and categorical variables were expressed as number and proportion as appropriate. The statistical significance level was set at P,0.05. All statistical analyses were conducted using STATA version 11 (STATA Corp.).
Results
The baseline characteristics of the mPSL+PSL (n=65) and PSL (n=60) groups are described in 
Initial mPSL Use and First Remission of Proteinuria
During 3.6 years (interquartile range=2.0-6.9 years) of the entire observational period of the whole cohort (n=125), 65 (100.0%) and 58 (96.7%) patients in the mPSL+PSL and PSL groups, respectively, achieved first remission (Table 1) . Two patients in the PSL group were lost to followup before achieving remission at days 29 and 58. The mPSL+PSL group achieved first remission significantly earlier (cumulative probabilities of remission of the mPSL+PSL group versus the PSL group: 0.66 versus 0.37 at day 15, 0.88 versus 0.65 at day 30, and 0.94 versus 0.92 at day 90; log-rank test: P=0.006) ( Figure 1A ). Because add-on use of mPSL before the first remission was significantly higher in the PSL group than the mPSL+PSL group (6 [9.2%] patients in the mPSL+PSL group versus 13 [21.7%] in the PSL group, P=0.04) and the proportions of add-on use of other immunosuppressants before remission were comparable between the two groups (4 [6.2%] versus 5 [8.3%], P=0.66), earlier remission in the mPSL+PSL group can hardly be ascribed to subsequent immunosuppressive therapy given before first remission. To control for significant differences in baseline characteristics between the mPSL+PSL and the PSL groups, we computed the PS of initial use of mPSL using a multivariate logistic regression model. The model was well calibrated (Hosmer-Lemeshow goodness-of-fit test: P=0.27) and had moderate discrimination in determining initial use of corticosteroid (area under the receiver operating characteristics curve=0.71). In each PS tertile, no significant differences in baseline characteristics were observed between the mPSL+PSL and the PSL groups, indicating that they were well balanced (data not shown). Multivariate CPH models stratified by PS tertiles verified the significant association between initial use of mPSL and earlier remission (mPSL+PSL versus PSL: HR, 1.47; 95% CI, 1.01 to 2.14; P=0.04) ( Table 3) . After each patient in the mPSL+PSL group was matched to a patient in the PSL group with the closest PS, leading to 42 matched pairs with well balanced baseline characteristics (Table 4) , initial use of mPSL+PSL was also identified as a significant predictor of earlier remission in the model matched by PS (HR, 1.93; 95% CI, 1.04 to 3.61; P=0.04) ( Table 3) .
Initial mPSL Use and First Relapse of Proteinuria
After achieving remission, 32 (49.2%) patients in the mPSL+PSL group and 43 (74.1%) patients in the PSL group developed at least one relapse (up to eight and nine relapses, respectively) during the entire observational period (Table 1 ). In the mPSL+PSL group, 13 (40.6%), 4 (12.5%), 5 (15.6%), and 10 (31.3%) patients developed one, two, three, and four or more times of relapses during the entire observational period, respectively, whereas 16 (37.2%), 7 (16.3%), 3 (7.0%), and 17 (39.5%) patients did so in the PSL group, respectively. The incidence of relapse was significantly lower in the mPSL+PSL group than the PSL group (HR, 0.0; 95% CI, 0.0 to 0.5 versus HR, 0.5; 95% CI, 0.0 to 0.7 relapses per person-year; P=0.007). Cumulative probabilities of first relapse in the mPSL+PSL group versus the PSL group were 0.28 versus 0.46 at year 1, 0.49 versus 0.60 at year 2, and 0.61 versus 0.80 at year 5, indicating that the incidence of first relapse was significantly lower in the mPSL+PSL group than the PSL group (logrank test: P=0.02) ( Figure 1B) . In univariate models, younger age, higher UP, and initial mPSL use were significantly associated with relapse (Table 2) . Multivariate adjustment for clinically relevant factors did not attenuate the association between initial use of mPSL and first relapse (mPSL+PSL versus PSL: HR, 0.50; 95% CI, 0.29 to 0.85; P=0.01) along with older age (per 10 year: HR, 0.81; 95% CI, 0.71 to 0.93; P=0.003) and higher UP level (per 1.0 ln g/d: HR, 1.36; 95% CI, 1.01 to 1.84; P=0.04). PS-based models also ascertained that initial use of mPSL was significantly associated with a lower incidence of relapse (mPSL+PSL versus PSL: HR, Figure 1 . | Earlier remission and lower incidence of relapse in patients with initial methylprednisolone use followed by prednisolone (mPSL+PSL group), compared with those with initial prednisolone use (PSL group). Cumulative probabilities of (A) first remission and (B) first relapse of mPSL+PSL group (n=65) and PSL group (n=60) were calculated using Kaplan-Meier method and compared using log-rank test.
0.55; 95% CI, 0.33 to 0.89; P=0.02 with stratification by PS tertiles; HR, 0.48; 95% CI, 0.23 to 0.98; P=0.04 with matching by PS) ( Table 3) . After excluding two patients censored before first remission, similar results were obtained (data not shown).
During the observational period before the first relapse (or censoring without relapse), no significant difference was observed between the mPSL+PSL and the PSL groups in the proportion of use of immunosuppressants and the point and cumulative PSL doses at months 1, 2, 3, 6, 12, 18, and 24 after initiating immunosuppressive therapy, with the exception of a significant but clinically minor difference in the point dose of PSL at month 1 (mPSL group [n=63]: HR, 0.69; 95% CI, 0.58 to 0.85 mg/kg per day; PSL group [n=54]: HR, 0.65; 95% CI, 0.53 to 0.77 mg/kg per day; P=0.04) (Figure 2 ). These data strongly suggest that immunosuppressive therapy was clinically comparable between the mPSL+PSL and the PSL groups.
Initial mPSL Use and Adverse Events
During a median 3.6 years (interquartile range=2.0-6.9 years) of the entire observational period, no patients progressed to ESRD requiring dialysis, and one patient in the mPSL group died of pancreatic cancer. No significant difference was observed between the mPSL+PSL and the PSL groups in hospitalization caused by infection (n=7 [ 
Discussion
This retrospective cohort study of 125 adult-onset MCD patients revealed that mPSL was associated with earlier remission of proteinuria and interestingly, lower incidence of relapses of proteinuria. In addition, baseline age and UP levels were identified as the predictors of remission and relapse, whereas baseline serum creatinine concentration was associated with remission only. There were several advantages of this study. First, it was the largest cohort of adult MCD patients in the world with a long observational period (median=3.6 years [interquartile range=2.0-6.9 years]). Second, it used PS-based models to deliberately control for the imbalance of baseline characteristics between the mPSL+PSL and the PSL groups. Third, immunosuppressive therapy during the observational period was carefully assessed.
Only a few past studies assessed the clinical impact of mPSL in adult MCD patients. A small Italian randomized controlled trial of 67 pediatric and 22 adult MCD patients reported no efficacy of mPSL in accelerating remission and reducing relapse in 22 adult MCD patients (19) . A Japanese retrospective cohort study reported a significantly higher incidence rate of relapse in patients treated with mPSL followed by PSL than in those patients who received PSL only (13) . Unfortunately, we cannot draw any conclusion on the antiproteinuric effect of mPSL from these studies, because prednisone and PSL dosing between mPSL-treated and untreated patients was quite different. By contrast, the present study showed that the mPSL+PSL and PSL groups received clinically comparative PSL dosing ( Figure  2 ), strongly suggesting that the initial mPSL use was associated with earlier remission and lower incidence of relapse.
Why did initial use of mPSL contribute to earlier remission and a lower incidence of relapse in MCD? Although the precise MCD pathogenesis remains unknown, immunologic perturbations, especially in T cells (26) , and subsequent injury to glomerular podocytes (27) , including reduced expression of nephrin (28) (29) (30) , lead to massive proteinuria in MCD. In addition to its immunomodulatory effect, corticosteroid directly affects the gene expression of podocytes (31) . Dexamethasone promotes the expression of nephrin and other proteinuria-associated factors in human podocytes in a dose-dependent fashion within a range corresponding to the intravenous mPSL therapy used in this study (31) . Thus, the effectiveness of mPSL +PSL in this study may be partly ascribed to the higher initial dose of corticosteroid, which normalized podocyte function more strongly. However, the lower relapse rate in the mPSL+PSL group during the several years of the observational period is hardly explained by the higher initial dose of corticosteroid in the mPSL+PSL group. One potential hypothesis for the long-term suppression of relapse by initial use of mPSL may be epigenetic modification (26) . Because corticosteroid induces epigenetic changes (32, 33) and because DNA methylation in PBMCs is modified in MCD patients (34) , altering between remission and relapse (35), the higher initial dose of corticosteroid administered in the mPSL+PSL group may possibly induce long-term epigenetic changes, leading to a long-term suppression of relapse compared with the PSL group. Additional study is essential to clarify the various long-term impacts of different corticosteroid doses on podocytes and immune cells. This study had several limitations. First, a significant difference in use of intravenous 25% albumin, a potentially confounding therapeutic intervention (18) , suggests that therapeutic interventions between the mPSL+PSL and the PSL groups were not equal. Although the PSbased models (Tables 3 and 4 ) and careful assessment of immunosuppressive therapy during the observational period (Figure 2 ) indicated that the therapeutic interventions observed were comparable between the mPSL+PSL and the PSL groups, the differences in unobserved therapeutic interventions linked to initial use of mPSL potentially led to the biased estimate of its effectiveness. The efficacy of mPSL should be evaluated in a well designed randomized controlled trial. Second, high prevalence of the use of intravenous 25% albumin is common in adult MCD patients in Japan (13, 18) but not common in other countries. Although the multivariate-adjusted models in Table 2 showed that intravenous administration of 25% albumin did not affect remission (HR, 1.07; 95% CI, 0.67 to 1.70; P=0.78) or relapse (HR, 0.97; 95% CI, 0.54 to 1.73; P=0.91) and additionally, did not modify an association between initial use of mPSL and these outcomes (P for interaction=0.23 and P for interaction=0.80 in multivariate-adjusted models regarding first remission and first relapse as the outcome, respectively), efficacy of mPSL should be ascertained in the internationally standard treatment regimen. Third, this study assessed the effectiveness of mPSL for first remission and first relapse in adult MCD patients, not for multiple remissions and relapses in MCD patients with frequent relapses. A similar efficacy of mPSL for multiple remissions and relapses in MCD patients with frequent relapses remains to be elucidated.
In conclusion, this study revealed that initial use of mPSL was associated with earlier remission and lower incidence of relapse, providing novel insight into the strategy of adult-onset MCD treatment. Its efficacy should be examined in a well designed randomized controlled trial.
